231 related articles for article (PubMed ID: 29132121)
21. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis.
Bienvenu T; Sermet-Gaudelus I; Burgel PR; Hubert D; Crestani B; Bassinet L; Dusser D; Fajac I
Am J Respir Crit Care Med; 2010 May; 181(10):1078-84. PubMed ID: 20167849
[TBL] [Abstract][Full Text] [Related]
22. Genotype and phenotype in cystic fibrosis.
Zielenski J
Respiration; 2000; 67(2):117-33. PubMed ID: 10773783
[TBL] [Abstract][Full Text] [Related]
23. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection.
Ziedalski TM; Kao PN; Henig NR; Jacobs SS; Ruoss SJ
Chest; 2006 Oct; 130(4):995-1002. PubMed ID: 17035430
[TBL] [Abstract][Full Text] [Related]
24. The Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor Augments Mucociliary Clearance Abrogating Cystic Fibrosis Transmembrane Conductance Regulator Inhibition by Cigarette Smoke.
Raju SV; Lin VY; Liu L; McNicholas CM; Karki S; Sloane PA; Tang L; Jackson PL; Wang W; Wilson L; Macon KJ; Mazur M; Kappes JC; DeLucas LJ; Barnes S; Kirk K; Tearney GJ; Rowe SM
Am J Respir Cell Mol Biol; 2017 Jan; 56(1):99-108. PubMed ID: 27585394
[TBL] [Abstract][Full Text] [Related]
25. Transient receptor potential canonical channel 6 links Ca2+ mishandling to cystic fibrosis transmembrane conductance regulator channel dysfunction in cystic fibrosis.
Antigny F; Norez C; Dannhoffer L; Bertrand J; Raveau D; Corbi P; Jayle C; Becq F; Vandebrouck C
Am J Respir Cell Mol Biol; 2011 Jan; 44(1):83-90. PubMed ID: 20203293
[TBL] [Abstract][Full Text] [Related]
26. Lung arginase expression and activity is increased in cystic fibrosis mouse models.
Jaecklin T; Duerr J; Huang H; Rafii M; Bear CE; Ratjen F; Pencharz P; Kavanagh BP; Mall MA; Grasemann H
J Appl Physiol (1985); 2014 Aug; 117(3):284-8. PubMed ID: 24925982
[TBL] [Abstract][Full Text] [Related]
27. Aggregates of mutant CFTR fragments in airway epithelial cells of CF lungs: new pathologic observations.
Du K; Karp PH; Ackerley C; Zabner J; Keshavjee S; Cutz E; Yeger H
J Cyst Fibros; 2015 Mar; 14(2):182-93. PubMed ID: 25453871
[TBL] [Abstract][Full Text] [Related]
28. Cellular heterogeneity of CFTR expression and function in the lung: implications for gene therapy of cystic fibrosis.
Jiang Q; Engelhardt JF
Eur J Hum Genet; 1998 Jan; 6(1):12-31. PubMed ID: 9781011
[TBL] [Abstract][Full Text] [Related]
29. Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively?
Tiddens HA; Donaldson SH; Rosenfeld M; Paré PD
Pediatr Pulmonol; 2010 Feb; 45(2):107-17. PubMed ID: 20082341
[TBL] [Abstract][Full Text] [Related]
30. Cystic Fibrosis Transmembrane Conductance Regulator in Sarcoplasmic Reticulum of Airway Smooth Muscle. Implications for Airway Contractility.
Cook DP; Rector MV; Bouzek DC; Michalski AS; Gansemer ND; Reznikov LR; Li X; Stroik MR; Ostedgaard LS; Abou Alaiwa MH; Thompson MA; Prakash YS; Krishnan R; Meyerholz DK; Seow CY; Stoltz DA
Am J Respir Crit Care Med; 2016 Feb; 193(4):417-26. PubMed ID: 26488271
[TBL] [Abstract][Full Text] [Related]
31. Dysfunction in the Cystic Fibrosis Transmembrane Regulator in Chronic Obstructive Pulmonary Disease as a Potential Target for Personalised Medicine.
Carrasco-Hernández L; Quintana-Gallego E; Calero C; Reinoso-Arija R; Ruiz-Duque B; López-Campos JL
Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680554
[TBL] [Abstract][Full Text] [Related]
32. Cystic fibrosis transmembrane conductance regulator is expressed in mucin granules from Calu-3 and primary human airway epithelial cells.
LeSimple P; Goepp J; Palmer ML; Fahrenkrug SC; O'Grady SM; Ferraro P; Robert R; Hanrahan JW
Am J Respir Cell Mol Biol; 2013 Oct; 49(4):511-6. PubMed ID: 23742042
[TBL] [Abstract][Full Text] [Related]
33. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
34. Role of the amiloride-sensitive epithelial Na+ channel in the pathogenesis and as a therapeutic target for cystic fibrosis lung disease.
Mall MA
Exp Physiol; 2009 Feb; 94(2):171-4. PubMed ID: 19060118
[TBL] [Abstract][Full Text] [Related]
35. Role of cystic fibrosis transmembrane conductance regulator in patients with chronic sinopulmonary disease.
Gonska T; Choi P; Stephenson A; Ellis L; Martin S; Solomon M; Dupuis A; Dorfman R; Zielenski J; Ooi CY; Weiser W; Durie PR; Tullis E
Chest; 2012 Oct; 142(4):996-1004. PubMed ID: 22423042
[TBL] [Abstract][Full Text] [Related]
36. Cystic fibrosis transmembrane conductance regulator in human muscle: Dysfunction causes abnormal metabolic recovery in exercise.
Lamhonwah AM; Bear CE; Huan LJ; Kim Chiaw P; Ackerley CA; Tein I
Ann Neurol; 2010 Jun; 67(6):802-8. PubMed ID: 20517942
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic options for hydrating airway mucus in cystic fibrosis.
Tildy BE; Rogers DF
Pharmacology; 2015; 95(3-4):117-32. PubMed ID: 25823699
[TBL] [Abstract][Full Text] [Related]
38. Extracellular Vesicles' Role in the Pathophysiology and as Biomarkers in Cystic Fibrosis and COPD.
Di Gioia S; Daniello V; Conese M
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613669
[TBL] [Abstract][Full Text] [Related]
39. Role of CFTR in airway disease.
Pilewski JM; Frizzell RA
Physiol Rev; 1999 Jan; 79(1 Suppl):S215-55. PubMed ID: 9922383
[TBL] [Abstract][Full Text] [Related]
40. Emerging therapies in cystic fibrosis.
Anderson P
Ther Adv Respir Dis; 2010 Jun; 4(3):177-85. PubMed ID: 20530065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
